CervoMed(CRVO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CRVO CervoMed

Post-Market Trading 05-02 19:32:31 EDT

24.14

-0.03

-0.12%

盘后24.14

+0.000.00%

16:00 EDT

High24.69	Low23.86	Vol32.10K
Open24.17	D1 Closing24.17	Amplitude3.42%
Mkt Cap199.25M	Tradable Cap59.53M	Total Shares8.25M
T/O774.87K	T/O Rate1.30%	Tradable Shares2.47M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"CRVO","market":"US","secType":"STK","nameCN":"CervoMed","latestPrice":24.14,"timestamp":1714680000000,"preClose":24.17,"halted":0,"volume":32103,"hourTrading":{"tag":"盘后","latestPrice":24.14,"preClose":24.14,"latestTime":"16:00 EDT","volume":194,"amount":4683.16,"timestamp":1714680007482},"delay":0,"floatShares":2466200,"shares":8253741,"eps":-0.816059,"marketStatus":"Post-Market Trading","change":-0.03,"latestTime":"05-02 19:32:31 EDT","open":24.17,"high":24.69,"low":23.8623,"amount":774865.6921,"amplitude":0.034245,"askPrice":24.49,"askSize":2,"bidPrice":23.43,"bidSize":11,"shortable":3,"etf":0,"ttmEps":-0.816059,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1714694400000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":24.17,"postHourTrading":{"tag":"盘后","latestPrice":24.14,"preClose":24.14,"latestTime":"16:00 EDT","volume":194,"amount":4683.16,"timestamp":1714680007482},"volumeRatio":1.378083},"requestUrl":"/m/hq/s/CRVO","defaultTab":"news","newsList":[{"id":"2429199829","title":"CervoMed Updates Stakeholders on Clinical and Financial Status","url":"https://stock-news.laohu8.com/highlight/detail?id=2429199829","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2429199829?lang=en_us&edition=fundamental","pubTime":"2024-04-23 20:13","pubTimestamp":1713874393,"startTime":"0","endTime":"0","summary":"CervoMed (CRVO) has provided an announcement. CervoMed Inc. has made key details about its business, clinical studies, and financial health availab...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cervomed-updates-stakeholders-on-clinical-and-financial-status?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cervomed-updates-stakeholders-on-clinical-and-financial-status?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2426415326","title":"CRVO: $150 Million Financing Strengthens Balance Sheet; Topline Data for Phase 2b Trial in 4Q24…","url":"https://stock-news.laohu8.com/highlight/detail?id=2426415326","media":"Zacks Small Cap Research","top":-1,"share":"https://ttm.financial/m/news/2426415326?lang=en_us&edition=fundamental","pubTime":"2024-04-10 18:35","pubTimestamp":1712745300,"startTime":"0","endTime":"0","summary":"On March 5, 2024, CervoMed Inc.  announced the presentation of biomarker data from the AscenD-LB Phase 2a trial of neflamapimod in patients with dementia with Lewy bodies  was featured in a poster presentation at the 18th International Conference on Alzheimer’s and Parkinson’s Disease  2024. Another abstract presented by scientific collaborators from University College London  demonstrated p38 MAPK inhibition, including with neflamapimod, improved tau-induced axonal transport defects both in vitro and in a tauopathy mouse model.For the pure DLB patient population, the following graph shows that treatment with neflamapimod resulted in a significant correlation  between the effects of GFAP and clinical outcomes assessed by change from baseline to week 16 in CDR-SB , with increased GFAP being associated with worsening CDR-SB and a reduction in GFAP being associated with improved CDR-SB. There was no correlation observed in placebo-treated patients.In February 2024, CervoMed announced that","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/BbD8kajVfnukJE3Nf5yA6w--~B/aD02OTI7dz03ODg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/scr.zacks.com/fe668de84c904ffefc93765a5aaa451b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/BbD8kajVfnukJE3Nf5yA6w--~B/aD02OTI7dz03ODg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/scr.zacks.com/fe668de84c904ffefc93765a5aaa451b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/crvo-150-million-financing-strengthens-103500753.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2425735998","title":"Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), CervoMed (CRVO) and Teladoc (TDOC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2425735998","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2425735998?lang=en_us&edition=fundamental","pubTime":"2024-04-08 19:30","pubTimestamp":1712575811,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Inventiva (IVA – Research Report), CervoMed (CRVO – ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-inventiva-iva-cervomed-crvo-and-teladoc-tdoc?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-inventiva-iva-cervomed-crvo-and-teladoc-tdoc?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2424367444","title":"CervoMed Shares Operational and Financial Insights Online","url":"https://stock-news.laohu8.com/highlight/detail?id=2424367444","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2424367444?lang=en_us&edition=fundamental","pubTime":"2024-04-04 19:12","pubTimestamp":1712229151,"startTime":"0","endTime":"0","summary":"CervoMed (CRVO) has shared an update. CervoMed Inc. has released key insights about its business operations, clinical studies, and financial health...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cervomed-shares-operational-and-financial-insights-online?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cervomed-shares-operational-and-financial-insights-online?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2424097239","title":"Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2424097239","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2424097239?lang=en_us&edition=fundamental","pubTime":"2024-04-02 19:00","pubTimestamp":1712055600,"startTime":"0","endTime":"0","summary":"MIAMI, April 02, 2024  -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 69th Emerging Growth Conference on April 3 & 4, 2024.The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ldm8wneYHS9yfU2ej3bTbA--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/c4f5f7fb74321f8cf4d35709ef806d49","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ldm8wneYHS9yfU2ej3bTbA--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/c4f5f7fb74321f8cf4d35709ef806d49"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/presenting-emerging-growth-conference-69-110000672.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2424711800","title":"CervoMed GAAP EPS of -$0.82 beats by $1.23, revenue of $7.14M beats by $3.09M","url":"https://stock-news.laohu8.com/highlight/detail?id=2424711800","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2424711800?lang=en_us&edition=fundamental","pubTime":"2024-04-01 20:50","pubTimestamp":1711975820,"startTime":"0","endTime":"0","summary":"CervoMed press release : FY GAAP EPS of -$0.82  beats by $1.23. Revenue of $7.14M  beats by $3.09M. As of December 31, 2023, CervoMed had $7.8 million in cash and cash equivalents as compared to $4.1 million as of December 31, 2022.  The company currently expects its cash position as of December 31, 2023, along with the remaining funds to be received from the NIA grant received and the upfront private placement funding of $50.0 million announced March 28, 2024, and expected to be received by the company on April 1, 2024, will enable it to fund its operating expenses and capital expenditures through the end of 2025.   More on CervoMed  CervoMed stock soars on $149.4M private placement financing Historical earnings data for CervoMed Financial information for CervoMed","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4085558-cervomed-gaap-eps-of--082-beats-by-123-revenue-of-714m-beats-by-309m","is_publish_highlight":false,"gpt_icon":0},{"id":"2424713462","title":"CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2424713462","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2424713462?lang=en_us&edition=fundamental","pubTime":"2024-04-01 12:00","pubTimestamp":1711944000,"startTime":"0","endTime":"0","summary":"- Announced private placement of up to $149.4 million led by RA Capital Management with participation from Armistice Capital, Special Situations Funds and Soleus Capital; pro forma cash and cash equiv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/04/01/2855119/0/en/CervoMed-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Corporate-Updates.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2423143632","title":"Cervomed Inc. Braces for Impact: How Political Uncertainty and the Presidential Election Could Shake Up the Pharma Industry","url":"https://stock-news.laohu8.com/highlight/detail?id=2423143632","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2423143632?lang=en_us&edition=fundamental","pubTime":"2024-03-31 14:00","pubTimestamp":1711864842,"startTime":"0","endTime":"0","summary":"Cervomed Inc. (CRVO) has disclosed a new risk, in the Economy & Political Environment category. Cervomed Inc. faces considerable business risk due ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cervomed-inc-braces-for-impact-how-political-uncertainty-and-the-presidential-election-could-shake-up-the-pharma-industry?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cervomed-inc-braces-for-impact-how-political-uncertainty-and-the-presidential-election-could-shake-up-the-pharma-industry?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2423644647","title":"CervoMed Inc reports results for the quarter ended in December - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2423644647","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2423644647?lang=en_us&edition=fundamental","pubTime":"2024-03-30 05:56","pubTimestamp":1711749401,"startTime":"0","endTime":"0","summary":"* CervoMed Inc    reported a quarterly adjusted loss of 38 cents per share for the quarter ended in December.  The lone analyst forecast for the quarter was for a loss of 29 cents per share.    * Reve","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2423410009","title":"CervoMed Inc    expected to post a loss of 21 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2423410009","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2423410009?lang=en_us&edition=fundamental","pubTime":"2024-03-30 04:44","pubTimestamp":1711745075,"startTime":"0","endTime":"0","summary":"* CervoMed Inc     is expected to report resultson April 1 (estimated) for the period ending March 31 2024   * The Boston Massachusetts-based  company is expected to report revenue of $2 million, acco","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2422116115","title":"BRIEF-CervoMed Announces Up To $149.4 Mln Private Placement Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2422116115","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2422116115?lang=en_us&edition=fundamental","pubTime":"2024-03-28 22:59","pubTimestamp":1711637997,"startTime":"0","endTime":"0","summary":"March 28  - CervoMed Inc   :   * CERVOMED ANNOUNCES UP TO $149.4 MILLION PRIVATE PLACEMENT FINANCING JOINED BY LEADING HEALTHCARE INVESTORS   * CERVOMED INC: PRO FORMA CASH AND CASH EQUIVALENTS FROM UPFRONT PROCEEDS EXPECTED TO PROVIDE RUNWAY THROUGH END OF 2025   * CERVOMED INC: INTENDS TO USE NET PROCEEDS FROM PROPOSED FINANCING TO FUND RESEARCH & DEVELOPMENT OF ITS CLINICAL-STAGE PRODUCT CANDIDATE, NEFLAMAPIMODSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2422197558","title":"iBio, Mesoblast, Kodiak Sciences among healthcare movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2422197558","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2422197558?lang=en_us&edition=fundamental","pubTime":"2024-03-28 22:01","pubTimestamp":1711634510,"startTime":"0","endTime":"0","summary":"Gainers: Avalo Therapeutics  +263%. iBio  +35%. Mesoblast ADR  +20%. Universe Pharmaceuticals  +16%. CervoMed  +22%.  Losers: Kodiak Sciences  -20%. PAVmed  -9%. Oncology Institute  -9%. Sera Prognostics  -7%. BeyondSpring  -7%.  S&P 500 Health Care Sector +0.18% to 1725.1. Health Care Equipment & Services +0.11% to 2013.2. Pharmaceuticals, Biotechnology & Life Science which contributes 58% to index is +0.18% to 1406.9.  More on Health Care Select Sector SPDR  XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Johnson & Johnson, Boston Scientific least shorted stocks in S&P 500 healthcare sector for Feb-end Waters, Moderna most shorted stocks in S&P 500 health sector till Jan-end","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4084966-ibio-mesoblast-kodiak-sciences-among-healthcare-movers","is_publish_highlight":false,"gpt_icon":0},{"id":"2423412328","title":"CervoMed to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2423412328","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2423412328?lang=en_us&edition=fundamental","pubTime":"2024-03-28 20:05","pubTimestamp":1711627500,"startTime":"0","endTime":"0","summary":"BOSTON, March  28, 2024  (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company’","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/03/28/2854468/0/en/CervoMed-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422989261","title":"CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2422989261","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2422989261?lang=en_us&edition=fundamental","pubTime":"2024-03-28 12:30","pubTimestamp":1711600200,"startTime":"0","endTime":"0","summary":"Funding from new investors, including RA Capital Management, Armistice Capital, Special Situations Funds and Soleus Capital $50 million financing upfront with up to an additional $99.4 million tied to","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/03/28/2853996/0/en/CervoMed-Announces-Up-to-149-4-Million-Private-Placement-Financing-Joined-by-Leading-Healthcare-Investors.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2421973703","title":"CervoMed Inc    expected to post a loss of 29 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2421973703","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2421973703?lang=en_us&edition=fundamental","pubTime":"2024-03-21 04:05","pubTimestamp":1710965108,"startTime":"0","endTime":"0","summary":"* CervoMed Inc     is expected to report resultson March 22 (estimated) for the period ending December 31 2023   * The Boston Massachusetts-based  company is expected to report revenue of $2 million, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cervomed.com","stockEarnings":[{"period":"1week","weight":-0.0175},{"period":"1month","weight":0.0648},{"period":"3month","weight":1.9656},{"period":"6month","weight":1.2113},{"period":"1year","weight":3.0588},{"period":"ytd","weight":2.1678}],"compareEarnings":[{"period":"1week","weight":-0.01},{"period":"1month","weight":-0.0418},{"period":"3month","weight":0.0228},{"period":"6month","weight":0.1511},{"period":"1year","weight":0.2179},{"period":"ytd","weight":0.0527}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.077022},{"month":2,"riseRate":0.625,"avgChangeRate":0.136561},{"month":3,"riseRate":0.5,"avgChangeRate":0.023523},{"month":4,"riseRate":0.375,"avgChangeRate":-0.070824},{"month":5,"riseRate":0.5,"avgChangeRate":0.217272},{"month":6,"riseRate":0.142857,"avgChangeRate":-0.124037},{"month":7,"riseRate":0.142857,"avgChangeRate":-0.110506},{"month":8,"riseRate":0.571429,"avgChangeRate":0.012628},{"month":9,"riseRate":0.142857,"avgChangeRate":-0.097769},{"month":10,"riseRate":0.142857,"avgChangeRate":-0.022918},{"month":11,"riseRate":0.285714,"avgChangeRate":-0.087797},{"month":12,"riseRate":0.375,"avgChangeRate":-0.133972}],"exchange":"NASDAQ","name":"CervoMed","nameEN":"CervoMed"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CervoMed(CRVO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CervoMed(CRVO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CervoMed,CRVO,CervoMed股票,CervoMed股票老虎,CervoMed股票老虎国际,CervoMed行情,CervoMed股票行情,CervoMed股价,CervoMed股市,CervoMed股票价格,CervoMed股票交易,CervoMed股票购买,CervoMed股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CervoMed(CRVO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CervoMed(CRVO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}